6 May 2016 - Canadians requiring treatment for chronic iron overload have a new treatment option with the availability of Jadenu (deferasirox) following its recent approval by Health Canada.

Jadenu contains the same active ingredient (deferasirox) as Exjade. However, Jadenu film-coated tablet is a new oral formulation of deferasirox. Jadenu is a tablet that should be swallowed whole and that requires a different dosing regimen and method of administration compared to Exjade, which must be dissolved in liquid.

Jadenu should be swallowed whole with water or other liquids, preferably at the same time each day and should be taken on an empty stomach or with a light meal. For patients unable to swallow whole tablets, it can also be crushed and administered by sprinkling the full dose on a soft food such as yogurt or apple sauce.

For more details, go to: https://www.novartis.ca/en/news/media-releases/prjadenutm-deferasirox-management-chronic-iron-overload-now-available-canada